Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
HS#2000-1046
Study information
Scientific title
Acronym
Study hypothesis
Not provided at time of registration
Ethics approval
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Condition
Arthritis
Intervention
Participants were randomised to receive SAMe or Celebrex over two months. Pain, quality of life and musculoskeletal measures were assessed before, during and after the study.
Intervention type
Drug
Phase
Not Specified
Drug names
S-Adenosyl methionine (SAMe), celecoxib
Primary outcome measure
Not provided at time of registration
Secondary outcome measures
Not provided at time of registration
Overall trial start date
01/09/2000
Overall trial end date
01/09/2002
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Volunteers
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
61
Participant exclusion criteria
Not provided at time of registration
Recruitment start date
01/09/2000
Recruitment end date
01/09/2002
Locations
Countries of recruitment
United States of America
Trial participating centre
101 The City Drive
Orange
92868
United States of America
Funders
Funder type
Hospital/treatment centre
Funder name
University of California, Irvine, Medical Center (UCIMC) (USA)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
Results in: http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15102339
Publication citations
-
Results
Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW, S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]., BMC Musculoskelet Disord, 2004, 5, 6, doi: 10.1186/1471-2474-5-6.